Boston Scientific Corporation
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $104.0M | $347.0M | $-239.0M | $-119.0M | $-121.0M | $-4.07B | $441.0M | $-1.07B |
| Depreciation & Amortization | $844.0M | $815.0M | $769.0M | $725.0M | $689.0M | $683.0M | $717.0M | $816.0M |
| Depreciation | $279.0M | $270.0M | $274.0M | $287.0M | $279.0M | $288.0M | $296.0M | $303.0M |
| Amortization | $565.0M | $545.0M | $495.0M | $438.0M | $410.0M | $395.0M | $421.0M | $513.0M |
| Stock-Based Compensation | $127.0M | $116.0M | $107.0M | $103.0M | $105.0M | $108.0M | $128.0M | $150.0M |
| Net Cash from Operating Activities | $1.43B | $1.18B | $691.0M | $1.27B | $1.11B | $1.28B | $1.01B | $325.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $319.0M | $376.0M | $247.0M | $259.0M | $245.0M | $226.0M | $304.0M | $272.0M |
| Business Acquisitions | $560.0M | $408.0M | $1.73B | $486.0M | $274.0M | $366.0M | $370.0M | $199.0M |
| Net Cash from Investing Activities | $-1.01B | $-887.0M | $-2.19B | $-745.0M | $-475.0M | $-579.0M | $776.0M | $-468.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | $0 | $125.0M | $500.0M | $600.0M | $492.0M | — |
| Net Cash from Financing Activities | $110.0M | $-206.0M | $1.28B | $-150.0M | $-624.0M | $-764.0M | $-1.73B | $-508.0M |
| Net Change in Cash | — | $-123.0M | $-268.0M | $370.0M | $10.0M | $-60.0M | $54.0M | $-651.0M |
| Free Cash Flow | $1.11B | $806.0M | $444.0M | $1.01B | $865.0M | $1.05B | $704.0M | $53.0M |